Clinical trial · Interventional
Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy
A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination With Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-containing Regimen Which Includes 5-FU.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient accrual
Summary
Brief summary (as posted)
This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Digestive System Neoplasm | Malignant Digestive System Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Nausea and Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aprepitant | Drug | — | UNRESOLVED |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Dolasetron Mesylate | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (aprepitant, dolasetron mesylate, dexamethasone)
- description
- Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
- interventionNames
- Drug: Aprepitant
- Drug: Dexamethasone
- Drug: Dolasetron Mesylate
- type
- PLACEBO_COMPARATOR
- label
- Arm II (placebo, dolasetron mesylate, dexamethasone)
- description
- Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
- interventionNames
- Drug: Dexamethasone
- Drug: Dolasetron Mesylate
- Drug: Placebo
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have a diagnosis of GI malignancy and who are scheduled to receive their initial treatment with an oxaliplatin-containing regimen in combination with 5-fluorouracil; these include combinations such as fluorouracil, oxaliplatin, and leucovorin calcium (FOLFOX), FOLFOX + bevacizumab, FOLFOX + cetuximab * Standard antiemetic therapy with initial treatment must include the dolasetron and dexamethasone; the minimum adequate doses include either: * Dolasetron (Anzemet) 100mg PO/IV or 1.8mg/kg IV AND * Dexamethasone (Decadron) 10mg PO/IV * Patient must agree, as part of the informed consent, to keep a journal of the episodes of nausea, vomiting, retching, and amount of rescue medications used on days 1 to 5 (day 1 = day of treatment) * Signed informed consent Exclusion Criteria: * Allergy or intolerance to dolasetron and dexamethasone * Use of another antiemetic agent (5HT3 antagonists, phenothiazines, butyrophenones, cannabinoids, metoclopramide, or corticosteroids) within 72 hours of day 1 of the study * An episode of vomiting or retching within 24 hours before the start of the initial treatment with oxaliplatin-containing regimen * Severe concurrent illness other than neoplasia * Gastrointestinal obstruction or an active peptic ulcer * Radiation therapy to the abdomen or pelvis within 1 week before or after day 1 of the study * Absolute neutrophil count of less than 1.5 x 10\^9/L (unless physician approves to proceed with chemotherapy) or * Platelets less than 100 x 109/L (unless physician approves to proceed with chemotherapy) * Total bilirubin \> 2 x upper limits of normal * Patients who are pregnant or breast feeding * Patients who are non-English speaking * Patients with cancer-induced nausea and vomiting grade 1 or greater using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria
References
Publications (0)
Data not yet available